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AI = aromatase inhibitor; Arz = arzoxifene; ER = estrogen receptor; HT = hormonal therapy; iNOS = inducible nitric oxide synthase; LG268 = 
LG 100268; NMU = N-nitrosomethylurea; SERM = selective ER modulator; TGF-β = transforming growth factor β.
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Introduction
Hormonal (endocrine) therapy (HT) is one of the most
effective treatments for breast cancer in the adjuvant, the
metastatic, and the prevention settings. For more than two
decades, the anti-estrogen tamoxifen has been the HT of
choice for all stages of ER-positive breast cancer [1], and
tamoxifen is still the only approved agent, in the United
States, to reduce the risk of breast cancer in high-risk
women. Tamoxifen is a prototype of a class of drugs called
selective estrogen-receptor (ER) modulators (SERMs),
which exhibit anti-estrogen effects in the breast but
possess estrogen-like activity in other tissues such as
bone and blood [1]. This inherent mixed agonist/antago-
nist nature of tamoxifen is probably responsible for the two
major limits of its successful therapeutic promise, i.e.
tumor resistance, de novo or acquired, seen in many
patients, and its adverse effects in other tissues. Develop-
ments over the past two decades have led to potentially
more effective, less toxic, and safer HT agents that are
currently being implemented into the management of
breast cancer, or soon will be. This, in turn, brings the
challenge of determining the optimal use of these new
drugs, either in combination or in sequence, questions
that are currently under investigation in key preclinical
models and clinical trials. Two recently reported preclinical
studies — one by Long and colleagues [2] that demon-
strates the efficacy of anti-estrogens as second-line
therapy in breast tumors failing aromatase inhibitor (AI)
therapy, and one by Suh and colleagues [3] that shows
high synergism between arzoxifene and the new rexinoid
LG 100268 in treatment and prevention — make signifi-
cant contributions in this area and are discussed.
Aromatase inhibitors: clinical efficacy
Estrogen deprivation was suggested long ago as one of
the most efficient strategies to block ER action [4]. After
menopause, estrogen deprivation is most specifically
achieved using inhibitors that block the conversion of
adrenal androgens to estrogens by the enzyme aromatase
[5]. The third-generation nonsteroidal AIs anastrozole and
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letrozole have both shown, in postmenopausal women,
superior efficacy compared with tamoxifen as first-line
treatments for advanced breast cancer, and, at least for
letrozole, also as neoadjuvant therapy for ER-positive inva-
sive breast cancer (reviewed in [6]). Current results from
the ATAC study in postmenopausal women with early
ER-positive breast cancer further suggest that in the adju-
vant setting, an AI (anastrozole) is superior to tamoxifen in
terms of disease-free survival and in preventing contralat-
eral incidents [7]. These AIs may very soon occupy a
central role in the management of postmenopausal women
with hormone-dependent breast cancer. Previously, AIs
have proven effective in postmenopausal women with
metastatic breast cancer in whom tamoxifen has failed [8].
Breast cancers in patients treated with AIs as first-line
therapy for metastatic disease are likely to eventually
become resistant, but may still respond to another type of
HT. Therefore, as these AI agents move into the first line, it
is essential to establish appropriate second-line therapies.
This important clinical question was directly addressed by
Long and colleagues [2], using a preclinical model of
xenografts with intratumoral aromatase.
Intratumoral aromatase preclinical model
Clinical evidence suggesting that local production of estro-
gen may contribute to breast tumor growth and, therefore,
that intratumoral aromatase is a potential therapeutic target
[9] had led Brodie’s research group, almost 10 years ago,
to develop a valuable preclinical mouse model of intratu-
moral aromatase [5,10]. Tumors formed by ER-positive
MCF-7 human breast cancer cells stably transfected with
the human aromatase gene (MCF-7Ca) were grown in
ovariectomized nude mice. These tumor cells remain
hormone-dependent and, in the presence of aromatase
substrate, synthesize sufficient estrogen to stimulate tumor
formation and progression [5]. This system, which models
the low-estrogen state in postmenopausal women, has
proven to successfully predict some HT effectiveness in
such women with breast cancer. Thus, previous studies
from this model have shown that AIs, and especially letro-
zole, are more effective at suppressing tumor growth than
either tamoxifen or the pure potent anti-estrogen fulvestrant
(ICI 182,780; Faslodex) [5,11], and that the combination of
AIs with anti-estrogens is no better than treatment with an
AI alone. The superiority of AI agents over tamoxifen for the
treatment of postmenopausal women with advanced breast
cancer [6,12] and also over the combination of an AI plus
tamoxifen in the adjuvant setting [7], has indeed been con-
firmed in several key clinical trials. However, contrary to the
preclinical model prediction, two recent randomized
phase III trials comparing anastrozole with fulvestrant
showed either that fulvestrant is as effective as anastrozole
[13] or that fulvestrant is superior to anastrozole [14] for
advanced breast cancer in postmenopausal women. Such
discrepancies between the preclinical model and results
from human trials may be related to some differences in
doses, artifacts of single-cell-line analysis, or intrinsic differ-
ences in pharmacokinetics and metabolism of drugs
between human and mouse. These discrepancies empha-
size some limitations of preclinical models in general, and
of the intratumoral aromatase model in particular, and
should be taken into consideration when translating these
findings into the clinic.
Sequential therapy after first-line treatment
with aromatase inhibitor
The establishment of the optimal sequence of endocrine
therapies offers significant benefits to women with
hormone-sensitive metastatic breast cancer by prolonging
the treatment period during which HT can be used [8]. In a
recent study, Long and colleagues, using their intratumoral
aromatase model, investigated the optimal second-line
therapy for patients who fail AI therapy [2]. The authors have
taken both in vitro and in vivo approaches to define hor-
monal sensitivities of these AI-resistant tumor cells. In vitro,
aromatase-transfected MCF-7Ca cells were selected by
long-term estrogen deprivation to grow in estrogen-
depleted medium (UMB-1Ca). Aromatase activity in these
cells did not significantly change. Whole-cell ligand-binding
assays showed that these selected cells expressed ele-
vated levels of functionally active ER. Basal ER-transcrip-
tional activity was not affected in these cells (as assessed
by the level of progesterone receptor), but estrogen stimula-
tion led to a much higher induction of ER activity than in
parental cells. Importantly, however, this increased ER activ-
ity did not translate to an increased growth response to
estrogen, and the cells did not show hypersensitivity to low
estrogen levels, contrasting what was previously shown
with estrogen-deprived hormone-resistant MCF-7 cells that
do not overexpress aromatase [15]. Nevertheless, like the
parental MCF-7 cells [15], UMB-1Ca cells remained sensi-
tive to anti-estrogens, both in vitro and in vivo.
To model the clinical situation of treating post-
menopausal breast cancer patients after the failure of
AI, Long and colleagues took a second approach and
defined the anti-estrogen sensitivity of letrozole-resis-
tant MCF-7Ca xenografts. Resistant xenografts were
first selected by their acquired ability to grow in the
presence of the letrozole after long-term treatment; the
mechanism of resistance has yet to be defined. Resis-
tant tumors were transplanted and reestablished in
naive nude mice in the presence of aromatase sub-
strate, and mice were then treated with either anti-estro-
gens or AIs. Transplant growth was slowed significantly
by tamoxifen and even more effectively by the potent
anti-estrogen fulvestrant. Surprisingly, while these resis-
tant tumors were refractory to the AIs anastrozole and
formestane, they regained significant sensitivity to letro-
zole. The results therefore suggest that tumors that have
failed AI therapy would remain sensitive to second-line
therapy with anti-estrogens, and that they may also230
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respond to rechallenge with AI therapy. Some clinical
data have also suggested the possibility that resistance
to nonsteroidal AIs would not confer cross-resistance to
the steroidal AIs, and vice versa [8]. Whether the
increased cellular ER levels in the resistant tumors are
responsible for their enhanced sensitivity to anti-estro-
gen is still an open question. Without doubt, further
studies to investigate the underlying mechanisms
responsible for letrozole resistance are crucial for a
better understanding of how to circumvent or overcome
this resistance in the clinic.
The SERM arzoxifene in breast cancer
prevention and treatment
Since estrogens have a crucial role in breast cancer initia-
tion, proliferation, and metastasis [16], AIs and parallel
methods to eliminate endogenous estrogen may offer a
potent strategy for breast cancer treatment and preven-
tion. However, estrogens also play an indispensable role
in other organs [17], and therefore SERMs, which
possess anti-estrogen activity in the breast but preserve
some fundamental estrogen-like functions in other tissues,
may offer a more comprehensive and balanced tactic.
While tamoxifen was the first widely used breast cancer
prevention agent, and is still, along with raloxifene, under
active clinical testing for prevention applications, novel
SERMs with a more desirable tissue profile are needed.
Because of significant advances in understanding the
structure and function of ER, several leading and promis-
ing compounds are now under clinical development.
As discussed in two recent reports by Suh and colleagues
of Sporn’s group [3,18], the SERM arzoxifene (Arz) is one
of the more promising compounds. It is a new benzothio-
phene derivative similar to raloxifene. Arz acts as a potent
anti-estrogen in breast and uterine tissues [19] but pos-
sesses estrogen agonist activity to maintain bone density
and serum cholesterol. In comparison with tamoxifen, Arz
has shown a stronger and more durable antagonist activity
in breast cancer cell lines and xenografts [20,21]. Several
recent phase II clinical trials also reported high antitumor
activity of Arz in advanced breast and endometrial cancers
[22]. In their first report regarding Arz, Suh and colleagues
showed that Arz is a highly effective agent that is signifi-
cantly more potent than raloxifene for the prevention of
mammary tumors in a rat model [18]. All of the above
studies suggest that the SERM profile of Arz is excellent,
and that this agent therefore has great promise for breast
cancer treatment and prevention.
Arzoxifene in combination with the rexinoid
LG 100268 (LG268)
Recent preclinical studies have revealed the potential of
combinations of HT with other agents for both prevention
and treatment of breast cancer. These agents may act
indirectly through the ER, mainly by influencing ER bidirec-
tional crosstalk with other signaling pathways, or may act
independently of the ER pathway and affect stromal as
well as epithelial cells [23]. The rexinoids, selective
ligands for the retinoid X receptors [24], are more effective
in tissues that contain ER protein [25] and they exhibit
great potential for both chemoprevention and therapy of
cancer. Recent studies have also shown that rexinoids can
prevent ER-negative breast cancer as well [26].
In a follow-up report on Arz, Suh and colleagues [3] now
demonstrate the high efficacy as single agents, and the
striking synergy when combined, of Arz and the new rexi-
noid compound LG268 [24] for both treatment and pre-
vention of breast cancer. The authors again used the
N-nitrosomethylurea (NMU) rat model, an established
model for breast cancer development and progression
that produces hormone-dependent tumors [27] and has
been used successfully to predict the efficacy of chemo-
preventive hormonal agents. Prevention efficacy against
either early or more advanced premalignant lesions was
tested by starting the treatment either early or late after
the administration of NMU. Prevention of progression of
early lesions, which was first demonstrated for the LG268
compound in that paper, was dosage dependent for both
drugs. Importantly, when the two drugs were combined,
only very low dosages of both were needed to cause
meaningful reduction in tumor burden, a significant obser-
vation for the clinical setting to minimize toxicity. The high
efficacy of each of the drugs and their synergism, though
with higher dosages than in the prevention setting, was
further achieved in the treatment setting for both early and
advanced invasive breast cancer. As a single agent, each
drug was capable of slowing or arresting tumor growth,
but when the drugs were combined, a dramatic synergism
was seen, which resulted in almost complete tumor shrink-
age of even very large tumors in as short a time as 3
weeks after the beginning of treatment.
Although some of the inhibitory effects of both Arz and
LG268 are very likely due to direct actions on premalig-
nant or malignant mammary epithelial cells, Suh and col-
leagues hypothesized that part of the synergistic effect
may also be mediated by an effect on the stromal cells
that control the microenvironment of the tumor. To investi-
gate this hypothesis, they conducted several experiments.
Fibroblast cells were treated with Arz and LG268, either
alone or in combination, and the effect of their conditioned
medium on the growth of lung epithelial cells highly sensi-
tive to transforming growth factor β (TGF-β) [28] was
monitored. Growth inhibition of the epithelial cells was
induced only by medium derived from fibroblasts treated
with the combination of Arz and LG268, and not when the
drugs were administered as single agents. This inhibitory
effect was most likely related to TGF-β, since a blocking
antibody to TGF-β completely reversed the inhibition.
Furthermore, by examining induction of the important231
angiogenic factor inducible nitric oxide synthase (iNOS) in
the fibroblast cells, which is known to be inhibited by
TGF-β [29], the authors found that the induction was
almost entirely blocked by the combination of Arz and
LG268, whereas the compounds had little effect on the
expression of iNOS when used alone. Obviously, other
mechanistic studies, especially in the context of the NMU-
rat model, are needed to investigate further the intriguing
hypothesis that stromal TGF-β induction [30] is the conduit
by which Arz and LG268 synergistically induce tumor
regression, and to reveal other underlying mechanisms that
are responsible for this synergistic action on breast cancer
prevention and treatment. But regardless of these future
studies, the data discussed above, as also concluded by
the researchers, strongly suggest that clinical application
of the combination of Arz and LG268 should be consid-
ered for prevention as well as for treatment in both the
adjuvant and advanced breast cancer settings.
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